Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole-course Taming of Tumor-associated Macrophages from Central to Peripheral using Engineered Outer Membrane Vesicle Nanohybrids for Improved Immunotherapy [part 1: RNA-seq]

ABSTRACT: Only regulation of tumor-associated macrophages (TAMs) in tumor microenvironment (TME) is always insufficient to achieve satisfactory clinical outcome, and training of central progenitor cells of TAMs in bone marrow is a potential approach. To achieve the whole-course taming of TAMs from central to peripheral, we developed nanohybrids containing bacterial outer membrane vesicle (OMV), GM-CSF and SIRPα-Fc fusion protein, which were coated with calcium phosphate (CaP) shell. The surface CaP coating endowed nanohybrids with safe circulation, allowing them to reach both bone marrow and TME. In bone marrow, OMV and GM-CSF together induced trained immunity of central progenitor cells, indicating by transcriptional alterations and epigenetic remodeling, which was inherited to peripheral TAMs. In peripheral TME, OMV and SIRPα-Fc triggered M1-like TAM phagocytosis with subsequent CD8+ T cell activation.

ORGANISM(S): Mus musculus

PROVIDER: GSE212259 | GEO | 2025/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Whole-course Taming of Tumor-associated Macrophages from Central to Peripheral using Engineered Outer Membrane Vesicle Nanohybrids for Improved Immunotherapy [part 2: ATAC-seq]

Project description:Only regulation of tumor-associated macrophages (TAMs) in tumor microenvironment (TME) is always insufficient to achieve satisfactory clinical outcome, and training of central progenitor cells of TAMs in bone marrow is a potential approach. To achieve the whole-course taming of TAMs from central to peripheral, we developed nanohybrids containing bacterial outer membrane vesicle (OMV), GM-CSF and SIRPα-Fc fusion protein, which were coated with calcium phosphate (CaP) shell. The surface CaP coating endowed nanohybrids with safe circulation, allowing them to reach both bone marrow and TME. In bone marrow, OMV and GM-CSF together induced trained immunity of central progenitor cells, indicating by transcriptional alterations and epigenetic remodeling, which was inherited to peripheral TAMs. In peripheral TME, OMV and SIRPα-Fc triggered M1-like TAM phagocytosis with subsequent CD8+ T cell activation.

2025-08-01 | GSE212260 | GEO

Preclinical evaluation of the efficacy of anti-human SIRPα antibody for cancer immunotherapy using the MITRG humanized mouse model

Project description:Tumor-associated macrophages (TAMs) represent abundantly in the tumor microenvironment (TME) and are thought to be novel targets for cancer immunotherapy. To elucidate the antitumor effects of therapeutics targeting human TAMs in vivo, we have here established a preclinical tumor xenograft model using immunodeficient mice expressing multiple human cytokines (MITRG mice) and examined the anti-tumor effect of anti–human SIRPα antibodies SE12C3, which inhibit the interaction of CD47 on tumor cells and enhance Fcγ receptor-mediated phagocytosis of tumor cells by human macrophages. Humanized immune system (HIS)–MITRG mice particularly facilitate human macrophage differentiation following transplantation of human CD34+ hematopoietic stem and progenitor cells. HIS–MITRG mice promoted the growth of both cell line– and patient–derived B cell lymphoma and infiltration of human TAMs into the tumor. Treatment of rituximab with SE12C3 markedly inhibited B–cell lymphoma growth in HIS-MITRG mice. The inhibition of B–cell lymphoma growth depended on human macrophages and was attributable to the promotion of rituximab–mediated lymphoma cell phagocytosis by human macrophages. In addition, the treatment of rituximab with SE12C3 induced reprogramming of human TAMs towards the pro-inflammatory phenotype in the TME. Furthermore, we demonstrated that the treatment of rituximab with SE12C3 significantly inhibited diffuse large B–cell lymphoma patient–derived tumor growth in HIS–MITRG mice. Together, HIS–MITRG mice provide an excellent mouse model for in vivo preclinical evaluation of the anti-tumor effect of therapeutics targeting human TAMs in the TME, such as anti–human SIRPα antibodies.

2023-09-30 | GSE239693 | GEO

Multi-omic Characterization of Pancreatic Cancer-Associated Macrophage Polarization Reveals Deregulated Metabolic Programs Driven by the GMCSF-PI3K Pathway

Project description:The pancreatic ductal adenocarcinoma (PDA) microenvironment is composed of a variety of cell types and marked by extensive fibrosis and inflammation. Tumor-associated macrophages (TAM) are abundant, and they are important mediators of disease progression and invasion. TAMs are polarized in situ to a tumor promoting and immunosuppressive phenotype via cytokine signaling and metabolic crosstalk from malignant epithelial cells and other components of the tumor microenvironment (TME). However, the specific distinguishing features and functions of TAMs remain poorly defined. Here, we generated tumor-educated macrophages (TEM) in vitro and performed detailed, multi-omic characterization (i.e. transcriptomics, proteomics, metabolomics). Our results reveal unique genetic and metabolic signatures of TEMs, the veracity of which were queried against our in-house single cell RNA sequencing (scRNA-seq) dataset of human pancreatic tumors. This analysis identified expression of novel, metabolic TEM markers in human pancreatic TAMs, including ARG1, ACLY, and TXNIP. We then utilized our TEM model system to study the role of mutant Kras signaling in cancer cells on TEM polarization. This revealed an important role for GM-CSF and lactate on TEM polarization, molecules released from cancer cells in a mutant Kras-dependent manner. Lastly, we demonstrate that GM-CSF dysregulates TEM gene expression and metabolism through PI3K-AKT pathway signaling. Collectively, our results define new markers and programs to classify pancreatic TAMs, how these are engaged by cancer cells, and the precise signaling pathways mediating polarization.

2022-02-16 | PXD028632 | Pride

Nanobody engineered and photosensitiser loaded bacterial outer membrane vesicles potentiate anti-tumor immunity and immunotherapy

Project description:Bacterial outer membrane vesicles (OMVs) are promising as antitumor agents, but their clinical application is limited by toxicity concerns and unclear mechanisms. We engineered OMVs with CDH17 tumor-targeting nanobodies, enhancing tumor selectivity and efficacy while reducing adverse effects. These engineered OMVs function as natural stimulator of interferon genes (STING) agonists, activating the cyclic GMP-AMP synthase (cGAS)-STING pathway in cancer cells and tumor-associated macrophages (TAMs). Loading engineered OMVs with photoimmunotherapy photosensitizers further enhanced tumor inhibition and STING activation in TAMs. Combining nanobody-engineered OMV-mediated photoimmunotherapy with CD47 blockade effectively suppressed primary and metastatic tumors, establishing sustained antitumor immune memory. This study demonstrates the potential of nanobody-engineered OMVs as STING agonists and provides insights into novel OMV-based immunotherapeutic strategies harnessing the innate immune system against cancer. Our findings open new avenues for OMV applications in tumor immunotherapy, offering a promising approach to overcome current limitations in cancer treatment.

2025-03-28 | GSE272295 | GEO

Complex interaction of tumor-derived factors instructs the niche specific phenotypes of tumor-associated macrophages (in vitro RNA-Seq)

Project description:Despite the importance of tumor-associated macrophages (TAMs) in modulating anti-tumor immunity, the molecular determinants of their functional phenotypes remain elusive. Through a large-scale CRISPR screen, we discovered that tumor-derived lactic acid, PGE2, and GM-CSF collaboratively shape the highly conserved but mutually exclusive TAM phenotypes: MHC-II+ and angiogenic TAMs. Mechanistically, the dichotomous nature of these two phenotypes is driven by the antagonistic interactions between lactic acid/PGE2 and GM-CSF. Lactic acid and PGE2 coordinately induce the angiogenic gene program while suppressing the GM-CSF-induced MHC-II program at chromatin level. This mechanism leads to distinct spatial distribution of TAMs, with angiogenic TAMs in lactate-rich hypoxic regions and MHC-II+ TAMs outside these areas. Furthermore, in vivo genetic perturbation of TAMs showed that shifting TAMs to an interferon responsive program, triggered by Adar inactivation, substantially potentiates anti-tumor immunity. Our findings suggest a conserved mechanism of TAM polarization and a potential approach for reprogramming TAMs in immunotherapy.

2025-08-03 | GSE269028 | GEO

Complex interaction of tumor-derived factors instructs the niche specific phenotypes of tumor-associated macrophages (in vitro ATAC-Seq)

2025-08-03 | GSE269027 | GEO